Recuvyra
fentanyl
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Recuvyra has expired following the marketing-authorisation holder’s decision not to apply for a renewal.
This EPAR was last updated on 12/07/2017
Authorisation details
| Product details | |
|---|---|
| Name |
Recuvyra
|
| Agency product number |
EMEA/V/C/002239
|
| Active substance |
fentanyl
|
| International non-proprietary name (INN) or common name |
fentanyl
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QN02AB03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Eli Lilly and Company Limited
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
06/10/2011
|
| Contact address |
Eli Lilly and Company Limited
Lilly House Priestley Road Basingstoke Hampshire RG24 9NL United Kingdom |
Product information
13/10/2016 Recuvyra - EMEA/V/C/002239 - IB/0009/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Nervous system
Therapeutic indication
Therapeutic indication
For the control of pain associated with orthopaedic and soft tissue surgery in dogs.